Business Description
Kabra Drugs Ltd
ISIN : INE323K01017
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.26 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.2 | |||||
Debt-to-EBITDA | -0.45 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -69.8 | |||||
3-Year EPS without NRI Growth Rate | -59.4 | |||||
3-Year FCF Growth Rate | 5.8 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 100 | |||||
9-Day RSI | 100 | |||||
14-Day RSI | 100 | |||||
6-1 Month Momentum % | 21.22 | |||||
12-1 Month Momentum % | 78.52 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.92 | |||||
Quick Ratio | 2.92 | |||||
Cash Ratio | 1.25 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -126.3 | |||||
ROA % | -41.69 | |||||
ROIC % | -52.41 | |||||
ROC (Joel Greenblatt) % | -176.31 | |||||
ROCE % | -125.64 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 2.95 | |||||
Price-to-Tangible-Book | 2.94 | |||||
EV-to-EBIT | -7.13 | |||||
EV-to-EBITDA | -7.13 | |||||
EV-to-FCF | -39.41 | |||||
Price-to-Net-Current-Asset-Value | 3.01 | |||||
Price-to-Net-Cash | 23.39 | |||||
Earnings Yield (Greenblatt) % | -14.03 | |||||
FCF Yield % | -2.16 | |||||
Forward Rate of Return (Yacktman) % | -0.48 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Kabra Drugs Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ₹) | |||
EPS (TTM) (₹) | -6.26 | ||
Beta | -0.29 | ||
Volatility % | 28.97 | ||
14-Day RSI | 100 | ||
14-Day ATR (₹) | 0.012977 | ||
20-Day SMA (₹) | 9.455 | ||
12-1 Month Momentum % | 78.52 | ||
52-Week Range (₹) | 4.87 - 9.59 | ||
Shares Outstanding (Mil) | 10.08 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Kabra Drugs Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Kabra Drugs Ltd Stock Events
Event | Date | Price(₹) | ||
---|---|---|---|---|
No Event Data |
Kabra Drugs Ltd Frequently Asked Questions
What is Kabra Drugs Ltd(BOM:524322)'s stock price today?
When is next earnings date of Kabra Drugs Ltd(BOM:524322)?
Does Kabra Drugs Ltd(BOM:524322) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |